ACETAdicet Bio, Inc.
The Read
Historically, ACET stock showed modest volatility with a muted 2.
The schedule
- Wed4Nov
- Sun31Jan
- Wed12May
- Wed4Aug
Past
- Sun27Sep
Actual outcome: Bear · $6.29 at outcome
ACET experienced a sharp decline due to a significant earnings miss and downward guidance, which exceeded market expectations. The company reported lower-than-expected revenue and profit, signaling weaker-than-anticipated performance in its core business segments. This led to a re-rating of the stock, especially in the ultra-short term. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: -29.7% from 2026-09-25 to 2026-09-28 (~5.3σ vs typical 1d vol). Target evaluation date 2026-09-30 (not yet reached as of 2026-09-28). Confidence 95%.
ACET experienced a sharp decline due to a significant earnings miss and downward guidance, which exceeded market expectations. The company reported lower-than-expected revenue and profit, signaling weaker-than-anticipated performance in its core business segments. This led to a re-rating of the stock, especially in the ultra-short term. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: -29.7% from 2026-09-25 to 2026-09-28 (~5.3σ vs typical 1d vol). Target evaluation date 2026-09-30 (not yet reached as of 2026-09-28). Confidence 95%.
- Wed5Aug
Actual outcome: Bear · $8.11 at outcome
Adicet Bio reported an EPS actual of -1.88, matching the estimate, but the stock fell 12.9% as the market reacted to the $36.2M cash position and -$21.5M free cash flow burn rate, signaling concerns over long-term financial sustainability. The lack of positive guidance or strategic developments further pressured the stock, leading to the bearish outcome.
Q2 2026 results with a critical focus on cash runway, given the $36.2M cash position in Q1 against a -$21.5M free cash flow burn rate.
- Wed13May
Actual outcome: Bear · $7.34 at outcome
Stock fell 7.7% from event to outcome date, aligning with the bear trajectory.
Q1 2026 results and management commentary on burn rate and cash runway at Adicet Bio will set the near-term risk premium around its pre-revenue cell therapy pipeline, with the stock currently at $6.86 and expectations focused on how long the $38.9M year-end cash balance can fund trials without a near-term raise.